Compare Symbotic Inc (SYM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

SYM trades at $40.89, down 32% year-to-date and near 52-week lows, with bearish technical signals dominating. Fundamentally, the company shows mixed results with a $22.5 billion backlog and 20%+ revenue growth but negative EBITDA of -$48M and net loss of -$17M in 2025. Recent earnings misses and high customer concentration (85% revenue from Walmart) create uncertainty despite analyst optimism.

The stock presents a high-risk opportunity with significant upside potential if execution improves. Analyst consensus targets $60.33 (47% upside) but near-term risks include continued earnings misses, customer concentration, and weak technical momentum. The 2027 inflection point for new system deployments represents the key growth catalyst.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.